Lactobacillus acidophilus TW01 strain and probiotic composition and use thereof

By screening and culturing Lactobacillus acidophilus strain TW01 from coffee fermentation broth, the problem of low survival rate of Lactobacillus acidophilus under environmental factors has been solved, achieving high efficiency and stability of intestinal probiotic products, and improving product quality and consumer trust.

CN115806895BActive Publication Date: 2024-11-26I EATING LIGHT LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111085653.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-16
Publication Date
2024-11-26
Estimated Expiration
2041-09-16

AI Technical Summary

Technical Problem

Lactobacillus acidophilus has a low survival rate under environmental factors such as pH, temperature, humidity, air and light, which leads to unstable efficacy of probiotic products. As a result, there are large differences in the quality of Lactobacillus acidophilus products on the market, making it difficult for consumers to identify high-efficiency products.

Method used

Lactobacillus acidophilus strain TW01 isolated from coffee fermentation broth was screened and cultured. It has high acid and bile salt resistance. Its survival rate and immunomodulatory function in acidic and bile salt environments were verified by in vitro experiments. It can be used to prepare intestinal probiotic products.

Benefits of technology

Lactobacillus acidophilus TW01 exhibits good survival rate and immunomodulatory function in acidic and bile salt environments, making it suitable for preparing intestinal probiotic products, thereby improving product efficacy stability and consumer trust.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115806895B_ABST
    Figure CN115806895B_ABST
Patent Text Reader

Abstract

The present invention discloses a Lactobacillus acidophilus strain TW01 and a composition and use thereof, wherein the strain used is isolated from coffee fermentation liquid. The Lactobacillus acidophilus strain TW01 (L.acidophilus) shows good tolerance in both acid and bile salt resistance tests, and has good induction ability for cytokines, achieving the goal of balancing the gastrointestinal bacteria of the human body, and can be used as a health-care functional probiotic for the immune regulation function of the gastrointestinal tract of the human body.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention is a Lactobacillus acidophilus strain TW01 and its composition and use, especially a Lactobacillus strain isolated and cultured from coffee fermentation liquid. The Lactobacillus strain is inoculated in Lactobacilli MRS broth (MRSB), and after being cultured in an anaerobic environment at 37°C or above for at least 24 hours, it is placed in a freezer for storage; then taken out of the freezer, activated for a second time, and the original bacterial liquid is collected for tolerance test. Among them, the Lactobacillus acidophilus strain (Lactobacillus acidophilus) TW01 itself has a higher degree of acid resistance and bile resistance than other strains, showing good acid resistance and bile resistance. Its use can be applied to enhance the immune regulation function of the human gastrointestinal tract, and has the high potential to be developed as a health-care functional probiotic. Background Art

[0002] Lactobacillus acidophilus (L.acidophilus) is one of the common probiotic strains. It is a kind of bacteria that naturally exists in the human body, mainly located in the human gastrointestinal tract. Its function is to maintain the environment of balanced bacterial phase in the body, prevent and inhibit the growth of harmful bacteria, and avoid harmful bacteria from endangering human health. The life cycle of Lactobacillus acidophilus is very short. If it is not damaged by other factors, its life cycle is five days on average. However, modern people have great pressure in life, which leads to abnormal diet. The internal environment is not conducive to the survival of Lactobacillus acidophilus, so it will cause the content in the body to be too low. In order to improve this deficiency, it is necessary to develop a normal work and rest habit, cultivate an internal environment suitable for the survival of Lactobacillus acidophilus, or actively increase the consumption of probiotics, supplemented by the outside of the human body, so that Lactobacillus acidophilus can smoothly reach the gastrointestinal tract, especially stay in the organs of the small intestine to play a role, so as to adjust the body's functions and maintain the balance of the gastrointestinal tract.

[0003] There are more than a thousand kinds of bacteria, molds, yeasts, etc. in the human intestines, among which Lactobacillus acidophilus is a beneficial bacteria for the human body. When external pressure or spicy and greasy eating habits cause a burden on the body, an internal environment with an increase in bad bacteria is formed, leading to an imbalance of gastrointestinal flora, especially an increase in bad bacteria in the small intestine, which can cause discomfort such as diarrhea and flatulence, acute inflammatory bowel disease, or long-term chronic inflammation of the intestine. At present, the most effective way to improve intestinal diseases is to take medication, mainly taking common drugs such as anti-inflammatory drugs, immunomodulators, steroids, and antibiotics. However, taking too much medicine can cause drug addiction or other side effects in the human body. It may also induce intestinal microorganisms to decompose toxic products from drugs, which will burden the human body. The difference in the degree of metabolism of different drugs by human intestinal microorganisms will cause doctors to evaluate and stress medication.

[0004] Secondly, the method to improve intestinal diseases is to take Lactobacillus acidophilus strains and their compositions regularly and quantitatively. This probiotic has been widely used in the food manufacturing process for a long time. Government agencies in charge of health food at home and abroad, as well as people with professional knowledge and ability, have confirmed its safety through tests such as its infectivity, metabolic activity, endogenous activity, pharmacokinetics, pathogenicity and virulence. The experimental data show that in healthy people, the reports of harmful effects of using probiotics are almost zero. However, the problem encountered by the industry at present is that probiotics are very sensitive to environmental factors such as pH, temperature, humidity, air and light. Once made into preparations, the number of live colony-forming units (CFU) will decrease with the natural life cycle of the probiotic strain. In order for probiotics to be effective, probiotics must be able to survive, grow and replicate in the gastrointestinal tract. Otherwise, probiotics cannot play their existing effects, or the original existing effects will be rapidly reduced or completely lost due to the high sensitivity of probiotics to pH.

[0005] The difficulty encountered by the prior art is that the survival rate of Lactobacillus acidophilus is low. In the external natural environment or the internal human intestinal environment, it will be affected by environmental factors such as pH, temperature, humidity, air and light. This situation is a typical innate characteristic of Lactobacillus acidophilus and cannot be improved through acquired experiments. Therefore, the ingredients and efficacy of commercially available Lactobacillus acidophilus products vary greatly, which will directly affect the market price. Even high-priced Lactobacillus acidophilus products do not guarantee high efficacy. Consumers do not have professional knowledge and it is difficult to identify whether Lactobacillus acidophilus is a good probiotic. In fact, the efficacy of Lactobacillus acidophilus must be traced back to the strain of Lactobacillus acidophilus. Whether the strain itself has a high acid and bile salt tolerance and can successfully stay in the small intestine is an important indicator. The reason is that when food enters the small intestine, the small intestine stimulates the bile to discharge bile, and the pancreas secretes pancreatic juice, and the small intestinal glands secrete intestinal juice, bile and pancreatic juice. Bile, pancreatic juice, and small intestinal juice are strongly alkaline and can neutralize the strong acidity of gastric acid. Therefore, it can be seen that a good Lactobacillus acidophilus must have a high degree of acid and alkali resistance in order to be able to successfully exert its effect in the small intestine.

[0006] Lactobacillus acidophilus itself is highly sensitive to the environment, and its effectiveness can be greatly affected by the environmental factors it is in. Therefore, it is a very important experimental process to cultivate and screen Lactobacillus acidophilus with high acid and alkali resistance at the source. Lactobacillus acidophilus with high acid and alkali resistance can be taken orally, successfully reach the intestines and exert its effects, and is not affected by the high pH in the human body. Only good Lactobacillus acidophilus can be used in the manufacture of probiotic products. Studies have shown that the dosage of probiotics needs to be 10 8CFU or above can increase the survival and growth of probiotics in the gastrointestinal tract to a suitable number. 8 If the probiotics fail to reach the minimum number of CFU, the efficacy of the probiotics cannot be exerted, and even the minimum number of bacterial colonies cannot be reached, and the intended effect cannot be achieved. If the probiotics fail to exert their efficacy, even if health products containing Lactobacillus acidophilus are taken regularly and quantitatively every day, or even in increased doses, the efficacy will not be apparent, and the efficacy is equivalent to not taking the products. Summary of the invention

[0007] In view of the shortcomings of the prior art and the difficulties faced by the prior art, the present invention focuses on cultivating and screening Lactobacillus acidophilus TW01 with high acid and bile resistance, and using the strain in health foods with intestinal health and immune regulation functions. The Lactobacillus acidophilus TW01 of the present invention is isolated from coffee fermentation liquid, which is a specific strain obtained by fermenting Taiwan Gukeng coffee grounds and then separating the coffee fermentation liquid.

[0008] The Lactobacillus acidophilus TW01 of the present invention is a biological preservation material with a preservation number of DSM 33990 of the German DSMZ (full name: Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, i.e. the German Microbial Culture Collection Center), and a preservation date of August 2, 2021. The name is Lactobacillus acidophilus TW01. The Lactobacillus acidophilus TW01 is characterized by good tolerance, especially in acid resistance and bile resistance tests, and has a significantly good survival response. Among them, the strain has a good ability to induce cytokines, and it itself has high potential to be developed into a probiotic product with intestinal health and immune regulation functions.

[0009] The strain used in the Lactobacillus acidophilus TW01 of the present invention is isolated from coffee fermentation liquid. The isolation and preliminary screening of the strain are performed by serially diluting physiological saline and smearing on a culture medium. It is necessary to culture at 37°C or above in an anaerobic environment for at least 24 hours, and then perform preliminary screening and staining, and complete the purification and culture of the experimental strain.

[0010] In the acid resistance test of bacteria, because the survival rate of Lactobacillus is easily affected by pH value, especially below pH3, the bacteria will be most damaged. Therefore, in related research, the acid resistance experiment of Lactobacillus is the most important test to be completed in the first stage. The purpose is to study the tolerance of Lactobacillus bacteria to acidic environment. The acid resistance of Lactobacillus was studied by in vitro test at pH3. The results are as follows: Figure 1 shown.

[0011] The purpose of the present invention is to apply the Lactobacillus acidophilus TW01 to a probiotic product for intestinal health care. There will be bile salts (also known as bile salts) in the intestinal tract because bile salts are discharged into the intestinal tract and reabsorbed by the intestinal tract. The reabsorbed bile salts enter the liver through the portal system to make up for the deficiency of the ability of hepatocytes to synthesize bile acids. The bile salts are reabsorbed by the hepatocytes and converted into conjugated bile acids and discharged into the intestinal tract again, thus forming an enterohepatic circulation. It can be seen from this that in the test of bile salt tolerance of the strain, it is the test that should be completed in the second stage to know whether the Lactobacillus acidophilus TW01 of the present invention has the characteristic of bile salt tolerance.

[0012] Bile salts have the properties of surfactants in the digestive system, which is a growth inhibitor for microorganisms. This experiment used 0.3% bile salt to conduct an in vitro bile salt tolerance test. The results are as follows: Figure 1 As shown in the figure, except for K1-2 which had poor tolerance, most strains had a certain degree of tolerance to 0.3% bile salts. After 240 minutes of reaction with 0.3% bile salt solution, the survival rate of the strains was at least 10 5 CFU / mL and above.

[0013] Finally, the effect of probiotics on cytokines was determined by testing whether lactobacilli could stimulate differentiated RAW264.7 cells to produce MIL-10 and MIL-12p40. Lactobacilli were cultured and screened, and different lactobacilli samples or LPS were added to the wells according to the groups. 100ul of culture medium was also added to the negative control group as a blank control group. The samples collected in the experiment showed that the cytokines MIL-10 and MIL-12p40 were analyzed by enzyme-linked immunosorbent assay (ELISA). ELISA is a commonly used molecular biological detection technology, which is characterized by the fact that only a small amount of sample (100ul) is needed for detection, and it has high accuracy and sensitivity.

[0014] In the cytokine induction experiment, macrophages were added to L. paraplantarum (F3-4), L. rhamnosus (S2-1), L. acidophilus (B-1), L. rhamnosus (D-1) and other strains, and cultured for 24 or 48 hours. The concentrations of cytokines IL-10 and IL-12 were measured, and the ratio of IL-10 to IL-12 was calculated to preliminarily screen strains with potential for immune efficacy. Fig. 9 , Fig.10It can be seen that the concentration of strain B (L. acidophilus) is the highest, which is significantly higher than that of other strains and also higher than the concentration induced by LPS, indicating that strain B is the best test result, has a high tolerance to bile salts, and can have a high survival rate in high concentrations of bile salts. The Lactobacillus acidophilus TW01 and the composition thereof of the present invention can be used in the development and production of intestinal probiotics and immunomodulatory products. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The results are gastrointestinal tolerance test results of the Lactobacillus strains of the present invention.

[0016] Figure 2 It is the result of bacterial species identification of the present invention.

[0017] Figure 3 This is the identification result of the 16S rRNA gene sequences of the F2-2 strain of the present invention.

[0018] Figure 4 This is the identification result of the 16S rRNA gene sequences of the F3-4 strain of the present invention.

[0019] Figure 5 This is the identification result of the 16S rRNA gene sequences of the S2-1 strain of the present invention.

[0020] Figure 6 This is the identification result of the 16S rRNA gene sequences of the K1-2 strain of the present invention.

[0021] Figure 7 This is the identification result of the 16S rRNA gene sequences of the B-1 strain of the present invention.

[0022] Figure 8 This is the identification result of the 16S rRNA gene sequences of the D-1 strain of the present invention.

[0023] Fig. 9 The results of different probiotics of the present invention inducing cytokine IL-10 (A).

[0024] Fig.10 The results of different probiotics of the present invention inducing cytokine IL-12 (B). DETAILED DESCRIPTION

[0025] The Lactobacillus acidophilus TW01 of the present invention is an acid-resistant and bile-resistant probiotic strain, named Lactobacillus acidophilus TW01, which has been deposited in the German DSMZ (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) on August 2, 2021, and its deposit number is DSM 33990. The address of the German DSMZ is Inhoffenstraβe 7B, 38124 Braunschweig, GERMANY. This strain has its uniqueness and novelty and can be widely used in intestinal probiotic products. Therefore, TW01 is specially noted in the name, which means that the first strain of Lactobacillus acidophilus TW01 in Taiwan, China, which is highly acid-resistant and bile-resistant, is also a kind of probiotic strain.

[0026] The present invention verifies the Lactobacillus acidophilus TW01 of the present invention and its metabolites through in vitro experiments, and through cytokine induction tests, the application strains with immune efficacy are screened, showing that the Lactobacillus acidophilus TW01 of the present invention and its metabolites have good tolerance in acidic and bile salt environments, and can be used to prepare intestinal probiotic compositions. The composition is a medicine, a health food, or a food, which is administered to an individual orally and has an effect in the intestine.

[0027] According to the present invention, the operating procedures and parameter conditions for bacterial culture, chemical separation of mixtures, and chemical structure analysis are within the professional qualities and routine technical scope of those skilled in the art. As used herein, the term "metabolites" means substances secreted into bacterial culture fluid after metabolism by the bacteria when culturing bacteria, including the culture fluid in which the bacteria are cultured.

[0028] The strains F2-2, F3-4, S2-1, K1-2, B-1 and D-1 used in the present invention are all isolated from coffee fermentation broth. The drugs used in the experiment, ox-bile dehydrated, purified, sodium chloride and glycerol, are purchased from Sigma-Aldrich; Agar, Lactobacilli MRS broth and Tryptic soy broth are purchased from Difco; and the anaerobic gas production bag and API 50CHL test kit are purchased from Qixin Biotechnology Company.

[0029] In the step of strain separation, the raw materials were homogenized with a slapping homogenizer (iron stomach machine), the required sample amount was weighed, serially diluted with physiological saline, and 0.1 mL of the dilution was smeared on Lactobacilli MRS agar (MRSA) culture medium. After completion, it was cultured at above 37°C in an anaerobic environment for at least 72 hours.

[0030] In the steps of strain screening, the first step is to observe the microscopic characteristics of the bacteria, make a smear of the bacteria, and use an optical microscope to observe the characteristics, shape, and external structure of the bacteria at 400 to 1000 times magnification; the second step is to identify the bacteria by Gram staining. After the bacteria are made into a smear, Gram staining is performed in the order of crystal violet, iodine solution, 95% ethanol, and safranin, and the staining results are observed under an optical microscope, thereby completing the preliminary screening of the bacteria.

[0031] In the purification and cultivation step of the experimental strain, several single colonies were selected from the culture dish where the strain was isolated according to their appearance, separated by line drawing on the MRSA culture medium, and placed in an anaerobic incubator at 37°C or above for at least 72 hours. After the cultivation was completed, a single colony was selected from the culture medium, separated by line drawing, and placed on a new MRSA culture medium. This was repeated twice to obtain a pure strain.

[0032] In the step of strain preservation, the first step is the preservation of Lactobacillus strains. The Lactobacillus strains are inoculated into Lactobacilli MRS broth (MRSB) and cultured at 37°C or above in an anaerobic environment for at least 24 hours. The culture solution is centrifuged (1200g, 10 minutes) to separate the bacteria. After removing the supernatant, the bacteria are suspended in sterile physiological saline and centrifuged again (1200g, 10 minutes) to remove the residual culture medium. After repeating twice, the bacteria are suspended in freezing solution (sterile glycerol and MRSB are mixed in a 1:1 ratio), 2 ml is drawn into a freezing tube, and placed in a -80°C freezer for storage; the second step is the activation of the strain. The freezing tube in the -80°C freezer is taken out and placed in a 37°C water tank for warming, 100 μL is inoculated into 50 mL MRSB, and cultured at 37°C or above in an anaerobic environment for at least 24 hours, and then a secondary activation is performed to obtain the original bacterial solution for the experiment.

[0033] In the tolerance test, the first step is to prepare the test bacterial solution. The original bacterial solution for the experiment is centrifuged (1200g, 10 minutes) to separate the bacteria. After removing the supernatant, it is suspended with sterile saline and centrifuged again (1200g, 10 minutes) to remove the residual culture medium. After repeating twice, it is re-dissolved with saline to a bacterial solution concentration of about 10 8 CFU / mL is the test bacterial solution.

[0034] The second step is to enter the acid resistance test. Use 5N hydrochloric acid solution and 0.1N sterile sodium hydroxide solution to adjust the physiological saline to pH 2.0 and pH 3.0. This is the acid resistance test solution. Take 1mL of the test bacterial solution, add 1.5mL of sterile physiological saline, and then add 5mL of acid resistance test solution. After culturing at least 30 and 60 minutes at 37°C, take samples and analyze the lactobacillus count, expressed as log CFU / mL.

[0035] The third step is to enter the bile salt tolerance test, adding 0.3% and 0.5% (w / v) ox bile (Ox-biledehydrated, purified) to sterile saline, and adjusting the pH to 8.0 with 0.1N sterile sodium hydroxide solution to prepare a simulated bile salt solution. Take 1mL of the test bacterial solution, add 1.5mL of sterile saline, and then add 5mL of simulated bile salt solution. After culturing at least 240 minutes at 37°C, sample and analyze the lactobacillus count, expressed as log CFU / mL. The survival rate is expressed as Log final bacterial count / Log initial bacterial count × 100%.

[0036] In the method of bacterial identification, the first method is to use API kit, the kit used is API 50CHL, the original bacterial solution for the experiment is centrifuged (1200g, 10 minutes) to separate the bacteria, after removing the supernatant, it is suspended with sterile saline and centrifuged again (1200g, 10 minutes) to remove the residual culture medium, after repeating twice, it is re-dissolved with saline to a bacterial solution concentration of about 6X10 10 CFU / mL. Take 0.1mL of this bacterial solution and add it to 10mL API 50CHL Medium, which is the API test bacterial solution. Add 10mL of sterile water to the culture box, put the API test strip into the box, and inject the API test bacterial solution into the 50 test holes in the test strip, and seal each test hole with sterile mineral oil. Put it in an incubator above 35℃ and culture it, and observe and record the results for at least 24 and 48 hours. Compare the experimental results with the API web database to get the results of bacterial species identification.

[0037] The second method uses 16S rRNA identification. Take 1mL to 2mL of the test bacterial solution into an eppendorf, centrifuge and remove the supernatant, add the extract, shake and mix, and let it stand for 10 minutes. Pipette the supernatant into a new eppendorf, prepare a 100-fold dilution in another eppendorf, and add primers and dNTPs for PCR reaction. After multiple cycles, centrifuge and purify the product, run the gel and cut the 16S rRNA position and sequence it.

[0038] In the determination of the effect of probiotics on cytokines, whether Lactobacillus S2-1, F3-4, B-1, and D-1 can stimulate differentiated RAW264.7 cells to produce MIL-10 and MIL-12p40 was tested. RAW264.7 cells were scraped from the plate, centrifuged, and then dissolved in culture medium and the cell concentration was counted. The cells were prepared into 6.25×10 5 cell / well; 400μl / well, seeded into the well plate according to the group (400μ1 / well). On the second day, different lactobacillus samples or LPS were prepared, 100 and 200pg / mL were taken, and added to the well plate according to the group (100μ1 / well), and 100ul of culture medium was added to the negative control group (negative control) as a blank control group. After culturing for at least 24 hours or 48 hours, observe under an inverted fluorescence microscope, and centrifuge the supernatant at 10000rpm for 10 minutes, take the supernatant and freeze it at -20℃ for later use. Take the samples collected at 24 hours and 48 hours, analyze their cytokines MIL-10 and MIL-12p40 by ELISA, and draw a chart to get the results. Fig. 9 and Fig.10 Results shown.

[0039] The experimental results show that the Lactobacillus acidophilus TW01 of the present invention screened out 28 fermentation strains from 8 raw material samples. After preliminary screening, 6 strains, namely F2-2, F3-4, S2-1, B-1, D-1, and K1-2, were selected for testing. The appearance of the strains all belonged to white dome colonies, and the bacterial bodies were all cocci to bacilli under microscopic observation. The Gram staining results were all positive, and the catalyst reaction was negative, which all met the basic characteristics of lactobacilli.

[0040] The results of the acid resistance experiment show that the survival rate of Lactobacillus is very easily affected by pH value, especially below pH 3, which will cause the greatest damage to the bacteria. In related studies, most of the in vitro tests at pH 3 were used to study the acid resistance of Lactobacillus. The results are as follows: Figure 1 As shown in the figure, the six strains and the control strains that were initially screened did not perform well in terms of resistance to the pH 2 acid test solution. At 30 minutes, the survival rate of most strains decreased by 4 to 5 log values. After 60 minutes of reaction, strains such as F2-2, S2-1, and D-1 had completely died, while the remaining three strains had better resistance to low pH values. Among them, the best performing strain was F3-4, whose survival rate was not as good as B-1 at 30 minutes, but at 60 minutes, the survival rate could still be maintained at 10 3 CFU / mL and above, and its acid resistance was significantly higher than that of other strains.

[0041] The results of the bile salt tolerance test show that bile salt has the characteristics of a surfactant in the digestive system and is a growth inhibitor for microorganisms. The bile salt tolerance test of the present invention is carried out in vitro with 0.3% bile salt. The results are as follows: Figure 1 As shown in the figure, except for K1-2, which has poor tolerance, most strains have a certain degree of tolerance to 0.3% bile salts. After 240 minutes of reaction with 0.3% bile salt solution, the survival rate of the strains is at least 10 5 CFU / mL and above.

[0042] From the results of bacterial species identification, we know that the API 50CHL kit is used to identify bacterial species. Figure 2 As shown, all six strains belong to the genus Lactobacillus, namely Lactobacillus pentosus (F2-2), L. plantarum (F3-4), L. rhamnosus (S2-1), L. rhamnosus (K1-2), L. acidophilus (B-1), and L. rhamnosus (D-1).

[0043] After preliminary identification using the API kit, 16S rRNA gene sequences were used for identification, and the sequencing results were compared with the NCBI Blest results ( Figures 3 to 8 ), and found that the comparison results of the three strains F2-2, F3-4, and K1-2 were different from those of the API test, namely Leuconostoc mesenteroides (F2-2), L. citreum (K1-2), and L. paraplantarum (F3-4). Since the biochemical characteristics of the strains vary depending on the isolation source, and the 16S rRNA gene sequences identification uses the conserved fragments in the microbial genes for identification, it is more traceable than the API, so the 16S rRNA gene sequences identification results are regarded as the final identification results.

[0044] The results of cytokine determination showed that the cytokine induction test was carried out by culturing macrophages RAW 264.7 to a concentration of 6.25×10 5After adding 100 or 200 pg / mL of L. paraplantarum (F3-4), L. rhamnosus (S2-1), L. acidophilus (B-1), L. rhamnosus (D-1) and other strains, respectively, and co-culture for at least 24 or 48 hours. The concentrations of cytokines IL-10 and IL-12 were measured, and the ratio of IL-10 to IL-12 was calculated to preliminarily screen the application strains with potential for immune efficacy.

[0045] Depend on Fig. 9 , Fig.10 It can be seen that strain B (L.acidophilus) has the highest IL-10 concentration, whether at a concentration of 100 or 200 pg / mL, which is significantly higher than other strains and the concentration induced by LPS. After co-culture for at least 48 hours, it will be slightly lower than the induced concentration at 24 hours. The induction results of IL-12 are similar to those of IL-10. Strain B (L.acidophilus) can induce the highest IL-12 concentration, and there is no significant difference between 24 hours and 48 hours. Although strain D (L.rhamnosus) is lower than strain B (L.acidophilus) in IL-10 and IL-12, it is still significantly higher than strains F (L.plantarum) and S (L.rhamnosus).

[0046] In summary, strain B showed good tolerance in both acid and bile resistance tests, and had the best ability to induce cytokines. This strain (L. acidophilus) has the potential to be developed into a health-promoting probiotic for intestinal health and immune regulation. The Lactobacillus acidophilus strain TW01 and its composition of the present invention can be combined with a pharmaceutical, a health food, or a food to prepare products such as tablets, powders, and foods.

[0047] According to the present invention, the pharmaceutical product can be manufactured into a dosage form suitable for enteral administration using techniques well known to those skilled in the art, including, but not limited to: tablets, chewable tablets, film-coated tablets, orally dissolving tablets, sublingual tablets, capsules, sustained-release oral dosage forms, enteric-coated oral dosage forms, powders, solutions, injections, external preparations, and the like.

[0048] According to the present invention, food products can be used as food additives, added during raw material preparation or during the food production process by conventional methods, and formulated with any edible material to form food products for human and non-human animals to consume. The types of food products include, but are not limited to: beverages, fermented milk, yogurt, fermented foods, baked products, health foods, dietary supplements, and nutritional supplements.

[0049]

Biological Material Deposit

[0050] Deposit number: DSM 33990

[0051] Storage date: 2021 / 08 / 02

[0052] Depository: DSMZ-German Collection of Microorganisms (Deutsche SammlungvonMikroorganismen und Zellkulturen GmbH)

[0053] Address of the depository institution: Inhoffenstraβe 7B, 38124 Braunschweig, GERMANY.

Claims

1. A Lactobacillus acidophilus strain TW01, deposited in DSMZ, Germany, the full name of which is Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, whose deposit number is DSM 33990.

2. A probiotic composition comprising the Lactobacillus acidophilus TW01 strain as claimed in claim 1.

3. The probiotic composition according to claim 2, wherein the probiotic composition is a medicine, a food or a food additive.

4. Use of the Lactobacillus acidophilus TW01 strain as claimed in claim 1 for preparing a probiotic composition.

5. The use of the Lactobacillus acidophilus TW01 strain according to claim 4, wherein the probiotic composition is a medicine, a food or a food additive.